kleintier konkret, Table of Contents kleintier konkret 2014; 17(1): 3-6DOI: 10.1055/s-0033-1361515 newsletter|industrie|forschung Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart Allergischen Juckreiz kortisonfrei behandeln Wieland Beck Zoetis Deutschland GmbH , Christina Mandel Zoetis Deutschland GmbH › Author Affiliations Recommend Article Abstract Buy Article All articles of this category Full Text References Literaturverzeichnis 1 Collard T, Fielder A, Zayai J, Stegemann MR. The absorption, distribution, metabolism, and elimination of oclacitinib maleate, a novel Janus Kinase inhibitor, in the dog. J Vet Pharmacol Ther 2012; 35(3): 137-178 2 Cosgrove SB, Wren JA, Cleaver DM et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24(5): 479-487 3 European Medicines Agency. CVMP assessment report for Apoquel . (EMEA/V/C/002688/0000) 2013: 1-20 4 Marsella R, Sousa CA, Gonzales AJ, Fadok VA. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. JAVMA 2012; 241(2): 194-206 5 Zoetis (2012a): Study Number 1962C-60-10-A02, Field safety and efficacy of oclacitinib compared to placebo for the control of atopic dermatitis in client-owned dogs (Pivotal for US and EU). 6 Zoetis (2012b): Study Number 1962C-60-10-A17, Dose confirmation: replacement therapy for dogs removed from field safety and efficacy of oclacitinib compared to placebo for the control of atopic dermatitis in client-owned dogs protocol. 7 Zoetis (2012c): Study 5962C-85-08-364 (56364) (pivotal for EU), Efficacy and safety of oclacitinib for the treatment of pruritic dermatoses in dogs. 8 Zoetis (2012d): Study 5662C-85-08-363 (56363), Efficacy and safety of oclacitinib compared to Atopica for the treatment of atopic dermatitis in dogs. 9 Zoetis (2012e): Study Number 1462N-60-10-A29, Margin of safety study of oclacitinib administered for 26 weeks to adult dogs (new regimen).
